{"id":"imiquimod-and-interferon-alpha","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin reactions (erythema, erosion, scabbing)"},{"rate":null,"effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":null,"effect":"Systemic immune activation effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod is a TLR7/8 agonist that promotes dendritic cell maturation and Th1 immune responses. Interferon alpha binds to interferon-alpha receptors on immune and tumor cells, enhancing natural killer cell activity, macrophage activation, and antigen presentation. Together, this combination amplifies both innate and adaptive immune responses against target cells.","oneSentence":"Imiquimod activates toll-like receptors to stimulate innate immunity, while interferon alpha enhances antiviral and anti-tumor immune responses through multiple signaling pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:33:17.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (investigational combination therapy)"},{"name":"Basal cell carcinoma (imiquimod approved topically; combination investigational)"}]},"trialDetails":[{"nctId":"NCT00581425","phase":"PHASE4","title":"Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2007-12","conditions":"Basal Cell Carcinoma","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Imiquimod and Interferon alpha","genericName":"Imiquimod and Interferon alpha","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Biologic","firstApprovalDate":"","aiSummary":"Imiquimod and Interferon alpha have been studied in combination for the treatment of basal cell carcinoma, excluding the face and scalp. Imiquimod is a topical cream that stimulates the immune system, while Interferon alpha is an immunomodulatory protein that has been used to treat various conditions, including basal cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}